{
  "docId": "019de074-7886-752e-a283-7bf57c077b30",
  "docSlug": "0ac137ebdbf597da5ec73bb0ea218c10",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 31,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 21,
  "notes": "The slide uses a line chart to show MADRS score changes over 12 weeks, highlighting the 25mg dose efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7886-752e-a283-7bf57c077b30/16",
  "deckHref": "/decks/019de074-7886-752e-a283-7bf57c077b30",
  "deckJsonHref": "/decks/019de074-7886-752e-a283-7bf57c077b30.json",
  "deckAnchorHref": "/decks/019de074-7886-752e-a283-7bf57c077b30#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.27,
        "x": 0.65,
        "y": 0.38
      },
      "kind": "callout",
      "text": "Primary Endpoint: Difference vs 1mg at Week 3: 25mg Diff = -6.6, p value = <0.001; 10mg Diff = -2.5, p value = 0.184",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b7f560a-5cdd-451d-b19d-8427cad1bec5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.58,
        "x": 0.37,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Line chart showing MADRS score reduction over 12 weeks for 25mg, 10mg, and 1mg doses.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "009529a0-0f66-4abc-be7f-0db91f9037e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.3,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "list",
      "text": "OWNERSHIP: 22.5% | PRODUCT: Oral Psilocybin | PHARMACOLOGY: 5-HT2A-R agonist | FEATURES: Rapid onset | INDICATIONS: TRD, Anorexia, PTSD | STATUS: Phase 3 ongoing | IP: Proprietary formulation | HIGHLIGHT: Efficacy in Phase 2b",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1ee6f43-0868-4ba0-956c-59342538f83d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.58,
        "x": 0.37,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: Schedule 13D filed with the SEC as of November 29th, 2021, as amended. Note: MADRS = Montgomery-Åsberg Depression Rating Scale.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d08d730-9df4-45dc-8ab6-26f31d01c20a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.58,
        "x": 0.37,
        "y": 0.08
      },
      "kind": "title",
      "text": "COMP360 Phase 2b trial showed a rapid, sustained reduction in depressive symptoms",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a848fa56-148e-4d5a-89cb-ceb3c8924ec2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY: COMP360",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22f1dc23-e9e4-4b5f-8794-306946466f58",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 9,
      "beatId": "7fd3e95d-372d-48f7-909d-f8c5c51d3874",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document highlights various traction points, including clinical study results and data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "950e8c6a-84b3-4e40-922d-babfc065c43a",
      "evidence": "The document emphasizes the limitations of current treatments and the need for new solutions.",
      "position": 0,
      "objective": "Highlight the urgent need for innovation in depression treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}